Lurasidone (Lurasidone)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Neuroleptics

Included in the formulation
  • Latuda®
    pills inwards 
    Takeda Pharma A / S     Denmark
    • АТХ:

    N.05.A.E.05   Lurasidone

    Pharmacodynamics:

    Atypical antipsychotic.In the central nervous system, dopamine D2-receptors and serotonin 5-HT2A-receptors, stimulates serotonin 5-HT1A-receptors, due to what eliminates negative symptoms in patients with schizophrenia (poverty of speech, introversion, flattening of emotions).

    Pharmacokinetics:

    After oral administration, the empty stomach is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 2.5 hours. The connection with plasma proteins is 99%.

    Metabolism in the liver via cytochrome CYP3A4, with the formation of 2 active and 2 inactive metabolites.

    The half-life is 18 hours. Elimination with feces and kidneys.

    Indications:

    It is used to treat all forms of schizophrenia, the manic stage of manic-depressive psychosis.

    ICD-10

    V.F20-F29.F20   Schizophrenia

    V.F20-F29.F21   Chrysotile disorder

    V.F20-F29.F22   Chronic delusional disorders

    V.F20-F29.F25   Schizoaffective disorder

    V.F20-F29.F29   Inorganic psychosis, unspecified

    V.F30-F39.F30   Manic episode

    V.F30-F39.F31   Bipolar affective disorder

    Contraindications:

    Diseases of the hematopoietic system, intoxication and alcoholic psychoses,coma, myasthenia gravis, severe renal and hepatic insufficiency, prostatic hyperplasia, increased tendency to convulsions, epilepsy, angle-closure glaucoma, decompensated diseases of the cardiovascular system, intercurrent diseases with febrile syndrome, age of 18 years, lactation period, individual intolerance.

    Carefully:

    Renal and hepatic insufficiency of moderate severity, pregnancy, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. Applicable in pregnancy in cases where the expected effect exceeds the risk to the fetus, is contraindicated during lactation.

    Dosing and Administration:

    Inside, 40 mg once a day. The initial dose is 40 mg.

    The highest daily dose: 80 mg.

    The highest single dose: 80 mg.

    Side effects:

    Central and peripheral nervous system: drowsiness, depression, tardive dyskinesia.

    Hemopoietic system: granulocytopenia, agranulocytosis, thrombocytopenia.

    The cardiovascular system: tachycardia, hypotension, including orthostatic.

    Digestive system: hypersalivation, increased appetite and body weight.

    Musculoskeletal system: muscle weakness, low back pain.

    Dermatological reactions: a rash, itching.

    Sense organs: violation of accommodation.

    Reproductive system: dose-dependent hyperprolactinemia.

    Allergic reactions.

    Overdose:

    Areflexia, drowsiness, suicidal attempts, coma, convulsions, mydriasis, tachycardia, collapse, respiratory depression.

    Treatment is symptomatic.

    Interaction:

    Potentiates the effect of MAO inhibitors and agents that depress the central nervous system: antihistamines, narcotic analgesics, benzodiazepine derivatives, ethanol.

    With simultaneous administration of lurasidone and drugs that have a high degree of binding to blood plasma proteins (for example, warfarin), it is possible to increase the blood content of a free fraction of any of the active substances, which can lead to the occurrence of side effects.

    Contraindicated taking the drug with strong inhibitors of cytochrome CYP3A4 (ketoconazole) and strong inducers of cytochrome CYP3A4 (rifampicin).

    Special instructions:

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up